Macquarie Group LTD Akero Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $79.1 Billion
- Q2 2025
A detailed history of Macquarie Group LTD transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 39,478 shares of AKRO stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,478
Previous 30,000
31.59%
Holding current value
$1.9 Million
Previous $1.21 Million
73.48%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding AKRO
# of Institutions
297Shares Held
92.4MCall Options Held
1.64MPut Options Held
1.19M-
Janus Henderson Group PLC London, X06.74MShares$324 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$275 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$268 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$263 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$218 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.23B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...